




KDR-in-4

Chemical Properties

CAS No.: 408502-06-7 Formula: C23H25N3O3

Molecular Weight: 391.46
Appearance: N/A

Storage: 0-4°C for short term (days to weeks), or -20°C for long term (months).



Biological Description

Description	KDR-in-4 is an effective inhibitor of kinase insert domain-containing receptor (KDR/VEGFR2) (IC50: 7 nM).	
Targets(IC ₅₀)	KDR: 7 nM	
In vivo	At doses of 100 mg/kg, KDR-in-4 (p.o.) results in a 98% reduction in lesion size in the rat choroidal neovascularization (CNV) model. 30 mg/kg doses of KDR-in-4 shows a 70% and 80% reduction in lesion size in the laser CNV and rat oxygen-induced retinopathy (OIR) models, respectively [2].	

Solubility Information

Solubility	< 1 mg/ml refers to the product slightly soluble or insoluble
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.555 mL	12.773 mL	25.545 mL
5 mM	0.511 mL	2.555 mL	5.109 mL
10 mM	0.255 mL	1.277 mL	2.555 mL
50 mM	0.051 mL	0.255 mL	0.511 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 °C for 6 months; - 20 °C for 1 month. Please use it as soon as possible.

Reference

- 1. Fang YQ, et al. Efficient syntheses of KDR kinase inhibitors using a Pd-catalyzed tandem C-N/Suzuki coupling as the key step. J Org Chem. 2007 Feb 16;72(4):1341-6.
- 2. Kinose F, et al. Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor. Molecular Vision 2005; 11:366-373

Page 1 of 2 www.targetmol.com

Inhibitors · Natural Compounds · Compound Libraries

This product is for Research Use Only \cdot Not for Human or Veterinary or Therapeutic Use.

Tel:781-999-4286

E-mail:info@targetmol.com

Address:36 Washington Street, Wellesley Hills, MA 02481

Page 2 of 2 www.targetmol.com